Cangzhou Transforms Saline Land into "Golden Granary" through Innovation
Cangzhou, a prefecture-level city in eastern Hebei province, China, is leading a major initiative to convert its saline-alkaline land into a productive agricultural hub. Focused on boosting the overall production capacity of these lands, the city is rolling out a pilot development program supported by a comprehensive platform to address long-standing agricultural challenges.
New Farming Technologies Drive Agricultural Modernization
As part of this transformation, a new generation of farmers in Cangzhou is applying modern scientific practices and advanced management techniques to drive the modernization of local agriculture and the development of adjacent rural areas.
By implementing planting methods that emphasize high-density cultivation, labor-saving techniques, mechanization, and standardized operations, the number of pear trees per hectare has increased from approximately 900 to over 2,400. This approach has boosted yields to 45,000 kilograms per hectare, with more than 91% of the fruit classified as high-quality.
Additionally, the integration of navigation systems and autonomous farm machinery has enhanced operational efficiency by 20% to 30%, while reducing seed usage by some 20%.
Innovative Seeds Pave the Way for Cangzhou's 'New Granary'
Seeds, often called the 'chips' of agriculture, are central to Cangzhou's agricultural strategy. The city is emphasizing a model that aligns seed selection with land characteristics, integrating production, education, research, breeding, and promotion to drive innovation in crop varieties.
Spanning approx. 4,100 hectares, the Cangzhou Dry Alkaline Wheat Breeding Base has an annual breeding capacity of 18,000 tons. Eleven newly developed dry alkaline wheat strains are currently undergoing the approval process, while three new varieties, including Cangmai 18, have already received official approval.
The Chinese Academy of Sciences' Ecological Agricultural Experiment Station has made significant strides by cultivating salt-tolerant and drought-resistant wheat varieties. Notably, Xiaoyan 60 has been listed in the national crop varieties promotion directory, and Xiaoyan 155 has demonstrated an expert-verified yield of 6,178.5 kilograms per hectare.
At the Cangzhou Academy of Agricultural and Forestry Sciences, researchers are employing advanced technology to accelerate breeding processes. Using an artificial climate chamber capable of adjusting temperature, humidity, and other environmental conditions to simulate outdoor farmland, scientists are able to breed up to four generations annually, significantly enhancing breeding efficiency.
Specialty Agricultural Products Lead Emerging Culinary Trends
A growing array of specialty agricultural products from saline-alkaline land is making its way from fields to dining tables, quickly gaining popularity among health-conscious audiences.
Cangzhou is now become home to 15 leading dry alkaline wheat processors operating above the municipal level, with a combined annual production capacity exceeding 1 million tons. Among the standout products, Huanghua Dry Alkali Wheat has been included in the national regional public brand catalog and featured on the national 'local specialties' promotion list. Meanwhile, Cangzhou Dry Alkaline Wheat has achieved recognition as a provincial-level regional public brand. In addition, 19 dry alkali wheat strains developed in the city have received green food certifications.
The Institute of Agricultural Products Processing and Nutritional Health of the Chinese Academy of Agricultural Sciences (Cangzhou) has also established six research and development centers, including the Dry Alkali Wheat Processing and Products Innovation R&D Center, and the Fruit and Vegetable Food Manufacturing and Nutritional Health R&D Center.
View original content: https://www.prnewswire.com/news-releases/cangzhou-transforms-saline-land-into-golden-granary-through-innovation-302441257.html
SOURCE Xinhuanet
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
The Suite Life: Four Seasons Hotel Shenzhen Welcomes Travellers to Connect, Work and Unwind in Stylish Modern Suites
Offering a plethora of perks, these city-centre sanctuaries are now available SHENZHEN, China, July 21, 2025 /PRNewswire/ -- Four Seasons Hotel Shenzhen invites guests to experience unrivalled luxury in the heart of Shenzhen with a stay in one of its 32 inspirational suites. Designed with a contemporary touch, each spacious sanctuary combines modern comforts, artful elegance and personalised service to provide an ideal home base for discovering the city's cosmopolitan charms. Guests can choose from four distinct suite categories, all complemented by exclusive Executive Club privileges, including access to the 29th-floor Executive Club Lounge with gourmet dining, express check-in and bespoke concierge services. Additional benefits include a one-time minibar replenishment (excluding alcohol), a 30-minute Express Massage for two guests per bedroom once per stay (non-accumulative and not combinable with other promotions), and complimentary laundry service for two pieces per bedroom, per night. Thoughtfully curated, every detail ensures a seamless and elevated stay in the heart of the city. Whether seeking memorable moments with loved ones, productive connections with colleagues, or simply a quiet retreat to return to at the end of the day, the legendary care of Four Seasons delivers precisely what each guest needs. Set within the dynamic Futian District, the Hotel offers easy access to vibrant cultural attractions, premier shopping hubs and the Shenzhen Convention and Exhibition Centre. Presidential Suite: The crown jewel of the Hotel, the expansive Presidential Suite unfolds across 475 square metres (5,113 square feet), featuring three spacious bedrooms that can accommodate up to nine guests. Natural light fills the generous living and dining areas, perfect for hosting a variety of gatherings — from sit-down feasts at the eight-seater dining table to cocktail parties in the refined lounge space. An in-suite collection of contemporary art adds creative flair, while a private library promises to elevate 'me time'. Ambassador Suite: Tailored for families or groups of up to six, the Ambassador Suite instantly puts travellers at ease with its home-away-from-home feel. Extending over 180 square metres (1,937 square feet) of space, this private oasis can be configured as a one- or two-bedroom suite. The airy living area beckons guests to linger and unwind, while the cosy dining space brings everyone together for intimate meals. Soaring views provide a visual connection with the city's buzzing energy. Deluxe Suite: With floor-to-ceiling windows showcasing garden views, the Deluxe Suite sets the scene for an extraordinary urban escape. Spanning 93-103 square metres (1,001-1,108 square feet), these suites are tailored for work, play and everything in between. A dedicated workspace allows guests to attend to emails and calls, while the light-filled living area — separate from the bedroom — offers an ideal venue for entertaining friends and colleagues. Executive Suite: At the Executive Suite, guests are welcomed by sweeping views of lush greenery or the Exhibition Centre. Ranging from 68-88 square metres (732-947 square feet), these stylish retreats feature distinct living and sleeping areas — a thoughtful feature to enhance extended stays as well as family visits. Locally rooted artworks introduce guests to the region's unique creative sensibility. Executive Club Experience Perched on the 29th floor, the Executive Club Lounge elevates suite stays with complimentary gourmet dining and afternoon tea, along with services like express check-in and pressing to ensure a seamless experience. Privileges include one-hour usage of the Executive Club Meeting Room, compliments of the Hotel. Suite Offer & Benefits Now available at bar rates, all suites at Four Seasons Hotel Shenzhen come with an array of exclusive perks: Daily breakfast and access to Executive Club Lounge. Mini bar (excluding alcohol) replenished once during the stay. 30-minute Express Massage for 2 guests per bedroom once during the stay. Non-accumulative and cannot be combined with other promotions. 2 pieces laundry service per bedroom per night. Personalised concierge service. For reservations, please contact the Hotel at +86 (755) 8826 8888 or book directly via the Hotel website at About Four Seasons Hotel Shenzhen The Four Seasons Hotel Shenzhen is ideally located in the heart of the commercial district of Futian, across the Shenzhen Conference & Exhibition Center and a short walk from the Civic Center which houses the city's Municipal Hall and Museum as well as near the famed Shenzhen Concert Hall and Library. The Hotel is surrounded by 3 modern shopping malls and is a few steps away from the subway metro station and 10-minute drive to two Hong Kong borders of Huanggang and Futian. Built along contemporary lines, the Hotel features 266 rooms inclusive of 32 suites, a Club Lounge, Business Centre, four food and beverage outlets, and a grand ballroom with five other function venues plus unique outdoor multilevel terraces. View original content to download multimedia: SOURCE Four Seasons Hotel Shenzhen
Yahoo
2 days ago
- Yahoo
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis
PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 StudyThe MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to (NCT06400511). About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at and and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking StatementsThis press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. View original content to download multimedia: SOURCE Viatris Inc. Sign in to access your portfolio
Yahoo
2 days ago
- Yahoo
PR Newswire Empowers Brands for AI Search and Strategic Communications with Multichannel Content Amplification
Key features for optimizing content in an AI-driven search environment NEW YORK, July 18, 2025 /PRNewswire/ -- As Large Language Models (LLMs) rapidly transform the search landscape, PR Newswire is empowering communicators to excel through its advanced Multichannel Amplification™ services. PR Newswire helps organizations publish once and reach everywhere, enhancing topical authority and shaping favorable AI-generated summaries. Key Features of PR Newswire's Multichannel Amplification services: Topical Authority: Build and reinforce your brand's presence in authoritative search results by leveraging PR Newswire's industry-leading distribution network, designed to surface expert-driven content across major search engines and media outlets. This is crucial for establishing your brand as a trusted source in an LLM-driven search environment. AI-Friendly Optimization: Structure and distribute press releases that are easily understood and surfaced by AI models, including LLMs. This boosts your brand's visibility and positioning in AI-generated answers and summaries, ensuring your message is accurately interpreted and presented in the evolving search ecosystem. One Message, Multiple Missions: Whether it's media relations, investor updates, brand awareness, or thought leadership, PR Newswire enables you to fulfill multiple communications objectives through a single, strategically crafted piece of content, optimized for how LLMs process information. "PR Newswire's platform is built for today's evolving media landscape, deeply impacted by the rise of LLMs," said Jeff Hicks, Chief Product and Technology Officer at PR Newswire. "We're not just distributing press releases – we're giving brands the tools to influence conversations, rank as topical authorities, and be found in the ways people are searching today, which increasingly means through LLM-powered interfaces." Helpful resources Ready to enhance your brand's visibility in the age of AI? Learn more about PR Newswire's Multichannel Amplification services: Watch PR Newswire's recent on-demand webinar, "From Keywords to Conversations: How AI Search is Reshaping PR," to explore how smart distribution can maximize visibility in the age of AI and LLMs: About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at View original content to download multimedia: SOURCE PR Newswire
